Fly News Breaks for January 2, 2020
IMMU, GMAB, EXEL, DCPH, BPMC, AGIO, SGEN, INCY
Jan 2, 2020 | 07:42 EDT
As previously reported, Guggenheim analyst Michael Schmidt downgraded Incyte (INCY) to Neutral from Buy, stating that he now views the shares as fairly valued following their strong performance in 2019. Schmidt also downgraded Seattle Genetics (SGEN) to Neutral from Buy, citing the same rationale. Among the companies expected to be commercial in 2020 that he covers, Schmidt maintains Buy ratings on Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Deciphera (DCPH), Exelixis (EXEL), Genmab (GMAB), and Immunomedics (IMMU).
News For INCY;SGEN;AGIO;BPMC;DCPH;EXEL;GMAB;IMMU From the Last 2 Days
Oct 27, 2020 | 20:27 EDT
Goldman Sachs analyst Graig Suvannavejh raised the firm's price target on Genmab to DKK 2,320 from DKK 1,112 and keeps a Neutral rating on the shares. The analyst also introduces a price target of $37 on Genmab ADR's. Suvannavejh states that the company's execution has been "impressive" as he calls it the "best-in-class European biotechnology company" given its royalties from Darzalex, though after the stock's run-up over the past two hears, he sees risk-reward as "balanced" at current levels.